Formula 1

Exuma Biotech, formerly known as F1 Oncology, is a clinical-stage biotechnology company specializing in the development of next-generation CAR-T cell therapies for solid tumors. The company utilizes its proprietary iCAR (inhibitory CAR), cCAR (conditional CAR), and rCAR (rapid CAR) platforms to enhance the safety and efficacy of adoptive cell therapies in complex tumor microenvironments. Their lead programs focus on enabling subcutaneous administration of CAR-T cells, which aims to eliminate the need for lymphodepleting chemotherapy and simplify the treatment process. Exuma operates globally with research and clinical development facilities in the United States and Asia, targeting high-unmet-need indications such as renal cell carcinoma and non-small cell lung cancer.